These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37475845)

  • 1. Progress in immunotherapy for neuroendocrine neoplasm of the digestive system.
    Pan WX; Zhang XM; Hao SL; Han W
    World J Gastroenterol; 2023 Jul; 29(26):4174-4185. PubMed ID: 37475845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
    Weber MM; Fottner C
    Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives.
    Bai R; Li W; Cui J
    Cancer Biol Med; 2022 Oct; 19(12):1649-61. PubMed ID: 36245210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Present and future of immunotherapy in Neuroendocrine Tumors".
    Albertelli M; Dotto A; Nista F; Veresani A; Patti L; Gay S; Sciallero S; Boschetti M; Ferone D
    Rev Endocr Metab Disord; 2021 Sep; 22(3):615-636. PubMed ID: 33851319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
    Xu G; Wang Y; Zhang H; She X; Yang J
    Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
    Kaur J; Vijayvergia N
    Curr Oncol; 2023 Sep; 30(9):8653-8664. PubMed ID: 37754542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
    Fazio N; Abdel-Rahman O
    Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) - Current literature review of diagnostics and therapy. What has changed in the management?
    Jurkiewicz K; Miciak M; Kaliszewski K
    Pol Przegl Chir; 2024 Mar; 96(4):58-66. PubMed ID: 39138986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms.
    Koumarianou A; Kaltsas GA; Chatzellis E; Kyriakopoulos G; Kolomodi D; Alexandraki KI
    Endocrine; 2021 Jul; 73(1):232-239. PubMed ID: 33544352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review.
    Regalla DKR; Deep O; Paluri RK
    Chin Clin Oncol; 2023 Dec; 12(6):67. PubMed ID: 38073310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Gastroenteropancreatic Neuroendocrine Neoplasia.
    Popa Ilie IR; Georgescu CE
    Neuroendocrinology; 2023; 113(2):262-278. PubMed ID: 34348340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
    Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
    Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
    Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
    Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives?
    Scoazec JY
    Ann Endocrinol (Paris); 2019 Jun; 80(3):163-165. PubMed ID: 31064659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Yin F; Wu ZH; Lai JP
    World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
    Klein O; Kee D; Markman B; Michael M; Underhill C; Carlino MS; Jackett L; Lum C; Scott C; Nagrial A; Behren A; So JY; Palmer J; Cebon J
    Clin Cancer Res; 2020 Sep; 26(17):4454-4459. PubMed ID: 32532787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
    Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.